Metsera (NASDAQ:MTSR) Shares Down 4.8% – Should You Sell?

Metsera, Inc. (NASDAQ:MTSR)’s share price was down 4.8% during mid-day trading on Tuesday . The stock traded as low as $25.62 and last traded at $25.91. Approximately 125,837 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 650,358 shares. The stock had previously closed at $27.22.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MTSR. Guggenheim began coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $56.00 price target for the company. Bank of America began coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 target price for the company. Cantor Fitzgerald assumed coverage on Metsera in a research report on Tuesday, February 25th. They issued an “overweight” rating on the stock. Finally, Evercore ISI began coverage on Metsera in a report on Tuesday, February 25th. They issued an “outperform” rating for the company.

Metsera Price Performance

Metsera (NASDAQ:MTSR) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($3.52) earnings per share (EPS) for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.